On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
Improving blood sugar may help reduce kidney stress
Maybe healthy foods that didnt taste as good in the past now taste better
Track Progress & Stay Consistent Consistency is key when using weight loss medications
Choco Banana Oat Muffins A soft, baked snack that combines oats, banana, and protein, best enjoyed in smaller portions
Follow us: 2026 Equalan Pharma
